BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
4.110
-0.220 (-5.08%)
At close: Dec 5, 2025, 4:00 PM EST
4.090
-0.020 (-0.49%)
After-hours: Dec 5, 2025, 7:52 PM EST
BioNexus Gene Lab Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | 9.47 | 9.51 | 9.77 | 10.93 | 13.36 | 11.39 | Upgrade
|
| Revenue Growth (YoY) | 2.21% | -2.66% | -10.60% | -18.21% | 17.31% | 8872.03% | Upgrade
|
| Cost of Revenue | 8.07 | 8.22 | 8.44 | 9.67 | 11.1 | 9.67 | Upgrade
|
| Gross Profit | 1.4 | 1.29 | 1.33 | 1.26 | 2.27 | 1.72 | Upgrade
|
| Selling, General & Admin | 3.86 | 4 | 3.04 | 1.73 | 1.28 | 1.33 | Upgrade
|
| Research & Development | 0.06 | 0.05 | 0.05 | - | - | - | Upgrade
|
| Other Operating Expenses | -0.1 | -0.06 | -0.04 | -0.25 | -0.07 | -0.18 | Upgrade
|
| Operating Expenses | 3.85 | 3.19 | 4.37 | 1.48 | 1.21 | 1.15 | Upgrade
|
| Operating Income | -2.45 | -1.9 | -3.04 | -0.22 | 1.06 | 0.57 | Upgrade
|
| Interest Expense | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.22 | 0.13 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -2.33 | -1.7 | -2.92 | -0.23 | 1.04 | 0.56 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.04 | 0.11 | 0.31 | -0.07 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.71 | Upgrade
|
| Pretax Income | -2.37 | -1.59 | -2.61 | -0.3 | 1.04 | 1.26 | Upgrade
|
| Income Tax Expense | -0.07 | 0 | 0.02 | 0.05 | 0.29 | 0.17 | Upgrade
|
| Net Income | -2.3 | -1.6 | -2.63 | -0.36 | 0.75 | 1.09 | Upgrade
|
| Net Income to Common | -2.3 | -1.6 | -2.63 | -0.36 | 0.75 | 1.09 | Upgrade
|
| Net Income Growth | - | - | - | - | -31.31% | - | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 1.15% | 12.24% | 10.17% | 0.99% | 66.36% | 19.16% | Upgrade
|
| EPS (Basic) | -1.28 | -0.90 | -1.66 | -0.25 | 0.53 | 1.28 | Upgrade
|
| EPS (Diluted) | -1.28 | -0.90 | -1.66 | -0.25 | 0.53 | 1.28 | Upgrade
|
| EPS Growth | - | - | - | - | -58.71% | - | Upgrade
|
| Free Cash Flow | -2.76 | -2.46 | -1.97 | 0.5 | 0.01 | 0.13 | Upgrade
|
| Free Cash Flow Per Share | -1.54 | -1.38 | -1.24 | 0.34 | 0.00 | 0.15 | Upgrade
|
| Gross Margin | 14.77% | 13.56% | 13.61% | 11.52% | 16.96% | 15.10% | Upgrade
|
| Operating Margin | -25.85% | -19.95% | -31.09% | -2.02% | 7.90% | 4.98% | Upgrade
|
| Profit Margin | -24.27% | -16.81% | -26.91% | -3.26% | 5.62% | 9.61% | Upgrade
|
| Free Cash Flow Margin | -29.17% | -25.88% | -20.18% | 4.55% | 0.04% | 1.15% | Upgrade
|
| EBITDA | -2.33 | -1.79 | -2.95 | -0.13 | 1.15 | 0.66 | Upgrade
|
| EBITDA Margin | -24.66% | -18.86% | -30.24% | -1.18% | 8.58% | 5.77% | Upgrade
|
| D&A For EBITDA | 0.11 | 0.1 | 0.08 | 0.09 | 0.09 | 0.09 | Upgrade
|
| EBIT | -2.45 | -1.9 | -3.04 | -0.22 | 1.06 | 0.57 | Upgrade
|
| EBIT Margin | -25.85% | -19.95% | -31.09% | -2.02% | 7.90% | 4.98% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 27.93% | 13.34% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.